Spots Global Cancer Trial Database for real world evidence
Every month we try and update this database with for real world evidence cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment | NCT06311383 | Breast Cancer | First-line Ribo... First-line endo... First-line chem... | 18 Years - | Novartis | |
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | NCT05701007 | Metastatic Cast... Metastatic Cast... | abiraterone enzalutamide docetaxel apalutamide cabazitaxel Radium-223 Lutetium-177 degarelix goserelin leuprorelin triptorelin | 18 Years - | Pfizer | |
Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT) | NCT04031898 | Lung Cancer | Non Interventio... | - | AstraZeneca | |
First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting | NCT04391283 | Carcinoma, Non-... | Osimertinib | 18 Years - | First Affiliated Hospital of Zhejiang University | |
PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc | NCT04814095 | Cancer | QOL CT imaging | 18 Years - | British Columbia Cancer Agency | |
Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT) | NCT04031898 | Lung Cancer | Non Interventio... | - | AstraZeneca | |
RWD Study in HER2+ mBC Patients in Third-Line Therapy | NCT04566458 | Breast Cancer S... | No intervention | 18 Years - | Exactis Innovation | |
First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting | NCT04391283 | Carcinoma, Non-... | Osimertinib | 18 Years - | First Affiliated Hospital of Zhejiang University | |
Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project | NCT02948088 | Giant Cell Tumo... | 18 Years - | Daiichi Sankyo | ||
RWD Study in HER2+ mBC Patients in Third-Line Therapy | NCT04566458 | Breast Cancer S... | No intervention | 18 Years - | Exactis Innovation | |
A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom | NCT04936399 | Esophageal Squa... | Nivolumab | 18 Years - | Bristol-Myers Squibb | |
PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc | NCT04814095 | Cancer | QOL CT imaging | 18 Years - | British Columbia Cancer Agency |